BIOMARIN PHARMACEUTICAL INC (BMRN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5B 3B 4.5B Q3 '21: 1.8B Q4 '21: 1.8B Q1 '22: 1.9B Q2 '22: 1.9B Q3 '22: 2B Q4 '22: 2.1B Q1 '23: 2.2B Q2 '23: 2.2B Q3 '23: 2.3B Q4 '23: 2.4B Q1 '24: 2.5B Q2 '24: 2.6B Q3 '24: 2.8B Q4 '24: 2.9B Q1 '25: 3B Q2 '25: 3.1B Q3 '25: 3.1B Q4 '25: 3.2B Q1 '26: 3.2B Q2 '26: 3.4B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 900M 1.8B 2.7B Q3 '21: 1.4B Q4 '21: 1.4B Q1 '22: 1.4B Q2 '22: 1.4B Q3 '22: 1.5B Q4 '22: 1.6B Q1 '23: 1.7B Q2 '23: 1.7B Q3 '23: 1.8B Q4 '23: 1.9B Q1 '24: 1.9B Q2 '24: 2.1B Q3 '24: 2.2B Q4 '24: 2.3B Q1 '25: 2.3B Q2 '25: 2.4B Q3 '25: 2.5B Q4 '25: 2.5B Q1 '26: 2.5B Q2 '26: 2.6B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-300M 0 300M 600M 900M Q3 '21: -68M Q4 '21: -82.3M Q1 '22: 29.9M Q2 '22: 57.4M Q3 '22: 108.2M Q4 '22: 161M Q1 '23: 86.1M Q2 '23: 112.5M Q3 '23: 145.4M Q4 '23: 185.8M Q1 '24: 211.8M Q2 '24: 266.7M Q3 '24: 350.1M Q4 '24: 484.2M Q1 '25: 619.6M Q2 '25: 776.1M Q3 '25: 615.5M Q4 '25: 409.5M Q1 '26: 315.2M Q2 '26: 149.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-250M 0 250M 500M 750M Q3 '21: 10.8M Q4 '21: -64.1M Q1 '22: 39.3M Q2 '22: 54.1M Q3 '22: 83.9M Q4 '22: 141.6M Q1 '23: 71.6M Q2 '23: 100M Q3 '23: 147M Q4 '23: 167.6M Q1 '24: 205.5M Q2 '24: 256.6M Q3 '24: 322.3M Q4 '24: 426.9M Q1 '25: 523.9M Q2 '25: 657.2M Q3 '25: 520.4M Q4 '25: 348.9M Q1 '26: 268.7M Q2 '26: 73M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 300M 600M 900M Q3 '21: 476.9M Q4 '21: 470.5M Q1 '22: 467.3M Q2 '22: 463.4M Q3 '22: 476.1M Q4 '22: 503M Q1 '23: 521.5M Q2 '23: 529M Q3 '23: 540.8M Q4 '23: 532.1M Q1 '24: 521.8M Q2 '24: 521.6M Q3 '24: 582M Q4 '24: 580.2M Q1 '25: 606.6M Q2 '25: 626.2M Q3 '25: 577.9M Q4 '25: 717.4M Q1 '26: 760.9M Q2 '26: 813.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

0 350M 700M 1.1B Q3 '21: 280M Q4 '21: 304.5M Q1 '22: 145.6M Q2 '22: 119M Q3 '22: 180.3M Q4 '22: 175.9M Q1 '23: 147.4M Q2 '23: 161.2M Q3 '23: 138.6M Q4 '23: 159.3M Q1 '24: 280.2M Q2 '24: 328.9M Q3 '24: 414.7M Q4 '24: 572.8M Q1 '25: 700.3M Q2 '25: 766.8M Q3 '25: 914M Q4 '25: 828M Q1 '26: 874.3M Q2 '26: 857.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

0 300M 600M 900M Q3 '21: 182.1M Q4 '21: 209M Q1 '22: 46.7M Q2 '22: 15.6M Q3 '22: 66.3M Q4 '22: 54.9M Q1 '23: 30.8M Q2 '23: 50.2M Q3 '23: 35.1M Q4 '23: 62.6M Q1 '24: 181.8M Q2 '24: 230.8M Q3 '24: 319.9M Q4 '24: 487.4M Q1 '25: 624.2M Q2 '25: 694.9M Q3 '25: 832.1M Q4 '25: 725M Q1 '26: 767.1M Q2 '26: 738.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '20: 187.2M Q2 '20: 180.7M Q3 '20: 197.7M Q1 '21: 184.4M Q2 '21: 185.4M Q3 '21: 183.2M Q1 '22: 194.9M Q2 '22: 187.4M Q3 '22: 185.6M Q1 '23: 194.4M Q2 '23: 195M Q3 '23: 191.2M Q1 '24: 199.3M Q2 '24: 200.5M Q3 '24: 197.1M Q1 '25: 196.5M Q2 '25: 197.1M Q3 '25: 192M Q1 '26: 197.7M Q2 '26: 194.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 0.00 1.50 3.00 4.50 Q3 '21: 0.07 Q4 '21: -0.36 Q1 '22: 0.18 Q2 '22: 0.26 Q3 '22: 0.42 Q4 '22: 0.73 Q1 '23: 0.37 Q2 '23: 0.51 Q3 '23: 0.76 Q4 '23: 0.87 Q1 '24: 1.06 Q2 '24: 1.32 Q3 '24: 1.66 Q4 '24: 2.21 Q1 '25: 2.70 Q2 '25: 3.38 Q3 '25: 2.67 Q4 '25: 1.80 Q1 '26: 1.39 Q2 '26: 0.39 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.